| Literature DB >> 30668921 |
Xin Zhang1, Liqi Wang1, Kai Qiu1, Doudou Xu1, Jingdong Yin1.
Abstract
The balance of myogenic and adipogenic differentiation is crucial for skeletal muscle homeostasis. Given the vital role of membrane proteins (MBPs) in cell signal perception, membrane proteomics was conducted to delineate mechanisms regulating differentiation of adipogenic and myogenic precursors in skeletal muscle. Adipogenic and myogenic precursors with divergent differentiation potential were isolated from the longissimus dorsi muscle of neonatal pigs by the preplate method. A total of 85 differentially expressed MBPs ( P < 0.05 and fold change ≥1.2 or ≤0.83) between 2 precursors were detected via isobaric tags for relative and absolute quantitation (iTRAQ) assay, including 67 up-regulated and 18 down-regulated in myogenic precursors. Functional enrichment analysis uncovered that myogenic and adipogenic precursors showed significant differences in cytoskeleton organization, syncytium formation, environmental information processing, and organismal systems. Furthermore, key MBPs in regulating cell differentiation were also characterized, including ITGB3, ITGAV, ITPR3, and EPHA2. Noteworthily, EPHA2 was required for myogenic differentiation, and it may promote myogenic differentiation through ERK signaling. Collectively, our study provided an insight into the distinct MBP profile between myogenic and adipogenic precursors in skeletal muscle and served as a solid basis for supporting the role of MBPs in regulating differentiation.-Zhang, X., Wang, L., Qiu, K., Xu, D., Yin, J. Dynamic membrane proteome of adipogenic and myogenic precursors in skeletal muscle highlights EPHA2 may promote myogenic differentiation through ERK signaling.Entities:
Keywords: adipogenesis; cell membrane proteins; myogenesis
Year: 2019 PMID: 30668921 PMCID: PMC6436648 DOI: 10.1096/fj.201801907R
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191
Primer sequences used in quantitative RT-PCR analysis
| Gene | Primer sequence, 5′–3′ | Product Size (bp) | |
|---|---|---|---|
| Forward | Reverse | ||
| PPARG | 135 | ||
| CEBPA | 71 | ||
| LPL | 297 | ||
| MYOD1 | 106 | ||
| Myogenin | 105 | ||
| Myomarker | 154 | ||
| EPHA2 | 194 | ||
| IL6ST | 117 | ||
| TMBIM1 | 107 | ||
| ATP1B1 | 150 | ||
| ERMP1 | 181 | ||
| ITGAV | 83 | ||
| MTX1 | 107 | ||
| ANTXR1 | 113 | ||
| S100A10 | 113 | ||
| ITPR3 | 199 | ||
| GGCX | 168 | ||
| ITGB3 | 142 | ||
| VCAM1 | 185 | ||
| SEMA3C | 83 | ||
| DERL1 | 107 | ||
| GALNT1 | 146 | ||
| TTYH3 | 185 | ||
| PTGFRN | 120 | ||
| DAG1 | 156 | ||
| JAM3 | 123 | ||
| FADS1 | 109 | ||
| TMEM209 | 154 | ||
| GAPDH | 219 | ||
Figure 1Differentiation of adipogenic and myogenic precursors isolated from the longissimus dorsi muscle of neonatal pigs. A) Oil Red O staining and immunofluorescence of adipogenic and myogenic precursors following 9 d of adipogenic induction and 4 d of myogenic induction, respectively. Oil Red O (red), Myosin (red), and DAPI (blue). B) Quantitative RT-PCR for expression level of adipogenic differentiation–related genes (PPARG, CEBPA, LPL) and myogenic differentiation–related genes (MYOD1, Myogenin, Myomarker) following adipogenic or myogenic induction. n = 4. Data are presented as means ± sem. A paired 2-tailed Student’s t test was used. Adi, adipogenic precursors; Myo, myogenic precursors. Scale bars, 100 μm. *P < 0.05, **P < 0.01 compared with adipogenic precursors.
Figure 2Proteomics analysis of adipogenic and myogenic precursors. A) Venn diagram exhibited the identification and quantification for total proteins and MBPs. B) The scatter plot for the determination of DEPs. The proteins with P < 0.05, and up- or down-regulated (FC ≥1.2 or ≤0.83) in myogenic precursors were shown in red or green, respectively. C) Transmembrane domains of all MBPs were predicted via TMHMM algorithm. Most MBPs contained 1 or 2 transmembrane domains. D) Differentially expressed MBPs were clustered on the heat map by the normalized expression abundance. E) Sixty-seven MBPs were up-regulated in myogenic precursors while 18 were down-regulated compared with adipogenic precursors. Adi, adipogenic precursors; Myo, myogenic precursors.
Up-regulated membrane proteins in myogenic precursors compared with adipogenic precursors
| Accession | Gene Name | Description | FC | TMHMM |
|---|---|---|---|---|
| Q3ZDR4 | CD70 | CD70 antigen | 3.44 | 1 |
| F1RWI1 | TRPA1 | Transient receptor potential cation channel, subfamily A, member 1 | 2.20 | 5 |
| F1SC45 | ENTPD1 | Ectonucleoside triphosphate diphosphohydrolase 1 | 2.15 | 2 |
| F1S567 | VCAM1 | Vascular cell adhesion protein 1 | 2.00 | 1 |
| F1SEQ7 | FAM213A | Redox-regulatory protein FAM213A | 1.96 | 1 |
| F1RT62 | ITGA3 | Integrin α-3 | 1.92 | 1 |
| P79388 | FOLR2 | Folate binding protein | 1.76 | 0 |
| F1RYT3 | SCARB2 | Scavenger receptor class B member 2 | 1.73 | 2 |
| F1SUT8 | EPHA2 | Ephrin type-A receptor 2 | 1.67 | 1 |
| I3LT41 | TMEM254 | Transmembrane protein 254 | 1.61 | 3 |
| F1SLL1 | IL6ST | IL-6 receptor subunit β | 1.61 | 1 |
| Q4U1U4 | CTSD | Cathepsin D | 1.60 | 1 |
| F1RQV6 | TMEM63B | Transmembrane protein 63B | 1.58 | 11 |
| I3LEZ3 | LSAMP | Limbic system associated membrane protein precursor | 1.57 | 1 |
| F1SPM5 | ANTXR1 | Anthrax toxin receptor 1 | 1.56 | 1 |
| F1RNP4 | P2RX4 | Purinergic receptor P2X, ligand-gated ion channel 4 | 1.56 | 2 |
| A0A0B8RTI6 | LNPEP | Leucyl and cystinyl aminopeptidase | 1.54 | 1 |
| K9J4M9 | COLEC12 | Collectin subfamily member 12 | 1.54 | 1 |
| I3LS87 | VASN | Vasorin | 1.51 | 1 |
| K9J6H1 | SEMA3C | Semaphorin-3C | 1.51 | 1 |
| F1S3H3 | ENTPD5 | Ectonucleoside triphosphate diphosphohydrolase 5 | 1.51 | 2 |
| K9J6J2 | STOM_tv1 | Erythrocyte band 7 integral membrane protein isoform A | 1.50 | 1 |
| F2Z5M2 | S100A10 | Protein S100-A10 | 1.48 | 1 |
| F1SJS6 | SIDT2 | SID1 transmembrane family, member 2 | 1.45 | 9 |
| I3L5W9 | TMBIM1 | Protein lifeguard 3 | 1.44 | 7 |
| A0A0B8RZM1 | DERL1 | Derlin | 1.43 | 5 |
| F1SAI6 | GALNT1 | Polypeptide N-acetylgalactosaminyltransferase | 1.42 | 1 |
| I3LLG6 | MXRA8 | Matrix remodeling associated 8 | 1.41 | 1 |
| P05027 | ATP1B1 | Sodium/potassium-transporting atpase subunit β-1 | 1.41 | 1 |
| A0A0B8RZR8 | ANPEP | Alanyl (Membrane) aminopeptidase | 1.39 | 1 |
| F1RZR0 | ITPR3 | Inositol 1,4,5-triphosphate receptor 3 | 1.38 | 7 |
| K7GRK4 | SLC2A13 | Solute carrier family 2 member 13 | 1.37 | 4 |
| F1RI78 | TTYH3 | Protein tweety homolog | 1.36 | 5 |
| F1SDC7 | ALDH3A2 | Aldehyde dehydrogenase 3 family member A2 | 1.36 | 1 |
| I3LK23 | B3GAT3 | Galactosylgalactosylxylosylprotein 3-β-glucuronosyltransferase | 1.35 | 1 |
| Q95JH1 | ITGB3 | Integrin β 3 | 1.35 | 2 |
| F1SMM0 | ERMP1 | Endoplasmic reticulum metallopeptidase 1 | 1.34 | 8 |
| I3LRE0 | BCAP29 | B-cell receptor associated protein 29 | 1.34 | 3 |
| A0A0B8RT32 | TAP1 | Transporter 1, ATP-binding cassette, subfamily B (MDR/TAP) | 1.32 | 7 |
| F1SF40 | MAN1A1 | Alpha-1,2-Mannosidase | 1.32 | 2 |
| F1SM21 | UGT1A6 | UDP-glucuronosyltransferase | 1.31 | 1 |
| F1SC82 | MYOF | Myoferlin isoform ×4 | 1.31 | 1 |
| K7GL05 | SLC44A1 | Solute carrier family 44 member 1 | 1.31 | 9 |
| I3LHT9 | STX12 | Syntaxin 12 | 1.30 | 1 |
| F1SAY0 | PTGFRN | Prostaglandin F2 receptor inhibitor | 1.30 | 1 |
| F1SA12 | TMEM205 | Transmembrane protein 205 | 1.30 | 3 |
| F1RUC0 | LAMP2 | Lysosomal associated membrane protein 2 | 1.29 | 1 |
| F1RTA1 | ABCC3 | ATP-binding cassette subfamily C member 3 | 1.29 | 14 |
| B8XSJ2 | ERLIN2 | ER lipid raft-associated 2 isoform 2 | 1.28 | 0 |
| M3TYA5 | KIAA0319L | KIAA0319-like protein | 1.28 | 2 |
| Q9TSW3 | SLA-3 | Leukocyte antigen 3/2 (SLA-3/2) | 1.27 | 1 |
| F1S268 | CREG1 | Cellular repressor of E1A stimulated genes 1 | 1.27 | 1 |
| F1SAN6 | ILVBL | ilvB acetolactate synthase like | 1.26 | 1 |
| B1A9P2 | SLA-2 | MHC class I antigen | 1.26 | 1 |
| I3LS60 | CARKD | ATP-dependent (S)-NAD(P)H-hydrate dehydratase | 1.26 | 1 |
| A2RQD8 | ITGAV | Alpha v integrin subunit variant | 1.25 | 1 |
| M3UYZ6 | ATP11A | Phospholipid-transporting atpase | 1.25 | 7 |
| F1SGJ4 | ABHD6 | Abhydrolase domain containing 6 | 1.25 | 1 |
| F1SPX9 | TMTC3 | Transmembrane and tetratricopeptide repeat containing 3 | 1.24 | 9 |
| F1SKK1 | SLC25A20 | Solute carrier family 25 member 20 | 1.24 | 3 |
| I3LB10 | GGCX | Gamma-glutamyl carboxylase | 1.23 | 5 |
| F1RLI6 | SLC25A46 | Solute carrier family 25, member 46 | 1.23 | 0 |
| M3VH66 | ANO10 | Anoctamin 10 | 1.23 | 8 |
| F1RQH9 | CD109 | CD109 molecule | 1.22 | 1 |
| F1SD42 | ADGRE5 | Adhesion GPCR E5 | 1.21 | 7 |
| A0A0B8S096 | DAG1 | Dystroglycan 1 (Dystrophin-associated glycoprotein 1) | 1.20 | 1 |
| F1RYJ7 | ZDHHC17 | Zinc finger DHHC-type containing 17 | 1.20 | 4 |
TMHMM, the number of predicted transmembrane helices.
Down-regulated membrane proteins in myogenic precursors compared with adipogenic precursors
| Accession | Gene Name | Description | FC | TMHMM |
|---|---|---|---|---|
| F1SPN1 | FKBP11 | Peptidylprolyl isomerase | 0.83 | 1 |
| F1S6C7 | JAM3 | Junctional adhesion molecule 3 | 0.82 | 2 |
| K7GK90 | SSR4 | Signal sequence receptor subunit 4 | 0.82 | 0 |
| F1S4R2 | ATL2 | Atlastin gtpase 2 | 0.82 | 2 |
| Q27HK4 | MTX1 | Metaxin-1 | 0.79 | 1 |
| K7N7E5 | FADS1 | Fatty acid desaturase 1 | 0.77 | 3 |
| F1RW78 | SSR1 | Signal sequence receptor subunit 1 | 0.75 | 1 |
| F1RM08 | SLC1A5 | Amino acid transporter (solute carrier family 1 member 5) | 0.74 | 9 |
| E7CXS1 | VLDLR | Very LDL receptor | 0.73 | 1 |
| I3LHM1 | GRIA2 | Glutamate receptor, ionotropic, AMPA2 (α 2) | 0.71 | 3 |
| Q19KI0 | RHCG | Ammonium transporter Rh type C | 0.70 | 12 |
| I3LHY0 | LOC100622780 | Lamina-associated polypeptide 2 isoform ×1 | 0.70 | 1 |
| Q6QRN9 | SLC25A6 | ADP/ATP translocase 3 | 0.69 | 2 |
| I3LQM7 | SLC38A5 | Sodium-coupled neutral amino acid transporter 5 | 0.69 | 11 |
| A5D9P2 | SLC39A7 | Solute carrier family 39 (Zinc transporter), member 7 | 0.69 | 7 |
| F1SMR8 | TMEM209 | Transmembrane protein 209 | 0.66 | 2 |
| F1S226 | VMP1 | Vacuole membrane protein 1 | 0.63 | 6 |
| F1SPG4 | NUP210 | Nucleoporin 210 | 0.48 | 2 |
TMHMM, the number of predicted transmembrane helices.
Figure 3GO enrichment analysis of differentially expressed MBPs. Clusters of significant GO terms (P < 0.05) for cellular component (A), molecular function (B), and biologic process were visualized using ReviGO (C). Node color intensity is scaled according the P value, and edge width indicates the degree of similarity.
Figure 4KEGG analysis of differentially expressed membrane proteins (MBPs). KEGG pathways (P < 0.05) were classified into 4 groups: Organismal Systems (A), Environmental Information Processing (B), Cellular Processes (C), and Human Diseases (D). Specific KEGG pathways included in each group were listed below. Expression changes of differentially expressed MBPs involved in each group were exhibited by heat maps. Adi, adipogenic precursors; Myo, myogenic precursors.
Figure 5Cluster of KEGG pathways and differentially expressed MBPs between adipogenic and myogenic precursors. KEGG pathways (P < 0.05) were based on differentially expressed MBPs. The green diamonds represent KEGG pathways, and red ellipses represent differentially expressed MBPs. Networks were visualized by Cytoscape (v.3.5.1).
Figure 6The mRNA expression pattern of key differentially expressed MBPs during myogenic differentiation. A) The mRNA expression of 22 differentially expressed MBPs identified in this study was altered during myogenesis of Pax7+ cells and Twist2+ cells isolated from mice (34), among them, 8 were up-regulated in DM, and 14 were down-regulated in DM. B–D) For myogenic precursors isolated from the skeletal muscle of pigs, quantitative RT-RCR analysis revealed that mRNA expression levels of 7 MBPs were significantly changed during myogenic differentiation (B), levels of 5 MBPs tended to be altered (C), and mRNA expression levels of 10 MBPs were not changed during myogenic differentiation (D). GAPDH was used as an internal control. n = 4. Data are presented as means ± sem. A paired 2-tailed Student’s t test was used. Tw2, Twist 2. *P < 0.05, **P < 0.01 compared with GM.
Figure 7The role of EPHA2 in myogenic differentiation. Myogenic precursors were treated EPHA2 inhibitor ALW-II-41-27 or transfected with siEPHA2 in GM before myogenic differentiation. A, B) p-EPHA2 (Tyr588), p-AKT (Ser473), p-REK (Thr202/Tyr204) levels of myogenic precursors treated with DMSO control or the ALW-II-41-27 (0.5 μM) in GM for 12 h. E, F) p-AKT (Ser473) and p-REK (Thr202/Tyr204) levels of myogenic precursors transfected with scrambled siRNA or siEPHA2 72 h in GM. GAPDH was used as a loading control. C, D, G, H) Representative immunofluorescence images (C, G) and MYOD1 and myosin levels analyzed by Western blot (D, H) on d 4 of myogenic differentiation for myogenic precursors treated with ALW-II-41-27 or transfected with siEPHA2. Myosin (red) and DAPI (blue) staining were shown. n = 3. Data are presented as means ± sem. An unpaired Student’s t test was used. CON, control; ALW, ALW-II-41-27. Scale bars, 100 μm. *P < 0.05, **P < 0.01.